{"id":"NCT01505647","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)","officialTitle":"A Phase III Double-Blinded, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Made With an Alternative Manufacturing Process (AMP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2012-07","completion":"2012-11","firstPosted":"2012-01-06","resultsPosted":"2013-07-03","lastUpdate":"2017-04-12"},"enrollment":498,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster","Shingles"],"interventions":[{"type":"BIOLOGICAL","name":"Zoster Vaccine, Live (AMP)","otherNames":[]},{"type":"BIOLOGICAL","name":"Zoster Vaccine, Live","otherNames":["ZOSTAVAX™","V211"]}],"arms":[{"label":"ZOSTAVAX™ (AMP)","type":"EXPERIMENTAL"},{"label":"ZOSTAVAX™","type":"ACTIVE_COMPARATOR"}],"summary":"This study will determine whether ZOSTAVAX™ made with an alternative manufacturing process \\[ZOSTAVAX™ (AMP)\\] is well tolerated and immunogenic, and has a comparable immune response to ZOSTAVAX™.","primaryOutcome":{"measure":"Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody","timeFrame":"Day 1 and Week 6 postvaccination","effectByArm":[{"arm":"ZOSTAVAX™ (AMP)","deltaMin":235.7,"sd":null},{"arm":"ZOSTAVAX™","deltaMin":208.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["37781954"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":330},"commonTop":["Injection-site pain","Injection-site erythema","Injection-site swelling","Injection-site pruritus"]}}